Royal Fund Management LLC Sells 4,654 Shares of Johnson & Johnson $JNJ

Royal Fund Management LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 16.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,426 shares of the company’s stock after selling 4,654 shares during the quarter. Royal Fund Management LLC’s holdings in Johnson & Johnson were worth $4,346,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. DeDora Capital Inc. lifted its holdings in shares of Johnson & Johnson by 3.3% during the 3rd quarter. DeDora Capital Inc. now owns 6,095 shares of the company’s stock worth $1,130,000 after acquiring an additional 197 shares during the period. JCIC Asset Management Inc. acquired a new position in Johnson & Johnson in the third quarter worth about $58,000. Defender Capital LLC. bought a new position in Johnson & Johnson during the third quarter worth about $234,742,000. Intrua Financial LLC boosted its holdings in Johnson & Johnson by 5.3% during the third quarter. Intrua Financial LLC now owns 16,951 shares of the company’s stock valued at $3,143,000 after purchasing an additional 850 shares in the last quarter. Finally, High Net Worth Advisory Group LLC grew its stake in shares of Johnson & Johnson by 1.1% in the 3rd quarter. High Net Worth Advisory Group LLC now owns 7,270 shares of the company’s stock valued at $1,348,000 after purchasing an additional 78 shares during the period. Institutional investors own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 revenue beat and 2026 guidance above consensus — management raised FY2026 sales and EPS targets, signaling mid‑single‑digit organic growth and margin improvement. Johnson & Johnson reports Q4 and Full-Year 2025 results
• Positive Sentiment: MedTech and oncology drove top‑line strength (MedTech up mid‑single digits; strong Darzalex and other cancer drug growth), supporting the company’s revenue trajectory beyond STELARA. Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth
• Positive Sentiment: Technicals and analyst sentiment remain constructive — MarketBeat highlights a trend‑following buy signal and rising analyst price targets, which could limit downside and support future upside. Johnson & Johnson Quietly Triggers a Trend Following Buy Signal
• Neutral Sentiment: EPS outcome was mixed: adjusted EPS roughly in line (small beat vs. some consensus figures) and margins broadly as expected — solid but not overpowering enough to eliminate near‑term concerns. Johnson & Johnson (JNJ) Tops Q4 Earnings and Revenue Estimates
• Negative Sentiment: Talc litigation advanced this week as plaintiffs cleared a key expert testimony hurdle — a reminder of legacy legal risk that can create episodic share pressure and potential liabilities. Johnson & Johnson Talc Plaintiffs Clear Key Expert Testimony Hurdle
• Negative Sentiment: STELARA sales plunged after loss of exclusivity and biosimilar competition (material YOY decline), which is a sizable headwind given STELARA’s previous revenue contribution. That dynamic is a key reason shares traded down despite the beat. J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales
• Negative Sentiment: Company flagged a hit from a recent drug‑pricing deal with the administration (described as “hundreds of millions” of dollars), which tempers net profit upside and adds near‑term uncertainty. Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Johnson & Johnson Trading Down 0.0%

JNJ opened at $218.12 on Thursday. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $220.11. The stock has a market capitalization of $525.52 billion, a PE ratio of 21.05, a PEG ratio of 2.24 and a beta of 0.34. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a 50-day moving average price of $207.39 and a two-hundred day moving average price of $188.27.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.46. The company had revenue of $24.56 billion for the quarter, compared to analyst estimates of $24.14 billion. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Johnson & Johnson’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent analyst reports. Morgan Stanley boosted their price target on Johnson & Johnson from $190.00 to $197.00 and gave the company an “equal weight” rating in a research note on Friday, December 12th. TD Cowen restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Johnson Rice set a $190.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday, October 22nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Finally, The Goldman Sachs Group lifted their target price on shares of Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $213.33.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.